English 中文简体 中文繁体

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of Hong Kong Stock Exchange, with the stock code:9966. With multiple in-house proprietary platforms of bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/immunology, and we are striving to develop next generation and best-in-class medicines to address unmet medical needs globally.

To combat the complexity of cancer, the ongoing development of cancer therapy requires multi-modality targeting treatments. Our technology platforms, such as bispecific and mixed-antibody platforms, have empowered us to fully take advantage of this trend by using innovative technology to integrate multiple distinct therapies into one molecule or one CMC process, with great potential to improve the efficacy and safety beyond current treatments. At Alphamab Oncology, developing the next generation biologics for cancer treatment is our passion and commitment.